FAQ

Determination of cefuroxime in human blood and urine using UHPLC-MS/MS and its application to stability study of cefuroxime over 278 days

Data publikacji: 16.12.2024

Archiwum Medycyny Sądowej i Kryminologii, 2024, Vol. 74 (3), s. 265 - 279

https://doi.org/10.4467/16891716AMSIK.24.020.20818

Autorzy

,
Karolina Nowak
Uniwersytet Opolski
Wszystkie publikacje autora →
,
Marcin Zawadzki
Department of Forensic Medicine, Wroclaw Medical University, Poland
https://orcid.org/0000-0003-2146-9724 Orcid
Wszystkie publikacje autora →
Paweł Szpot
Department of Forensic Medicine, Wroclaw Medical University, Poland
https://orcid.org/0000-0002-5352-3492 Orcid
Wszystkie publikacje autora →

Tytuły

Determination of cefuroxime in human blood and urine using UHPLC-MS/MS and its application to stability study of cefuroxime over 278 days

Abstrakt

Purpose: Forensically, the widespread use of antibiotics necessitates methods for their detection in biological materials to ascertain their role in adverse reactions or fatalities. Given the need to conduct toxicological studies on materials stored for extended periods under various temperature conditions, research on antibiotic stability in biological matrices over such durations is crucial for accurate toxicological assessments.

Methods: The stability of cefuroxime in blood and urine was determined for 278 days at three different temperatures: -15°C, +4°C, +23°C. The analyses were conducted using ultra-high-performance liquid chromatography coupled with triple-quadrupole tandem mass spectrometry. Results: The method met all validation requirements. This study also describes the results of the thermal stability of cefuroxime. Cefuroxime showed the greatest stability at -15°C and was highly unstable at room temperature (+23°C) in all types of studied biological matrices.

Conclusions: The study confirms instability of cefuroxime in blood and urine samples. Therefore, the analysis of this antibiotic in biological matrices for purposes such as forensic toxicology should be performed as soon as possible after sampling to avoid decline in concentration. In cases of prolonged material storage, the concentrations should be cautiously interpreted in the prepared expertise.

Bibliografia

Pobierz bibliografię

Gu J., Liu S., Zhi Y.: Cefuroxime-inducted anaphylaxis with prominent central nervous system manifestations: a case report. J Int Med. Res. 2019, 47(2), 1010–1014. doi:10.1177/0300060518814118

Tiglis M., Mester A., Hurmuzache T., et al.: Intraoperative anaphylactic shock following cefuroxime-axetil routine test care report and literature review. Rev Chim. 2019, 70(3), 925–928

Wurpts G., Aberer W., Dickel H., et al.: Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Society of Allergology (AeDA), German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Austrian Society for Allergology and Immunology (ÖGAI), and the Paul-Ehrlich Society for Chemotherapy (PEG). Allergol Select. 2020, 4, 11–43. doi:10.5414/ALX02104E

Scadding GW.: Providing an antibiotic allergy service. Clin Pulm Med. 2019, 26, 146–153. doi:10.1097/CPM.0000000000000325

Stepanovic B., Sommerfield D., Lucas M., von Ungern-Sternberg BS.: An update on allergy and anaphylaxis in pediatric anesthesia. Paediatr Anaesth. 2019, 29(9), 892–900. doi:10.1111/pan.13703

Azevedo J., Gaspar Â., Mota I., et al.: Anaphylaxis to beta-lactam antibiotics at pediatric age: six-year survey. Allergol Immunopathol (Madr). 2019, 47(2), 128–132. doi:10.1016/j.aller.2018.07.008

Sachs B., Dubrall D., Fischer-Barth W., Schmid M, Stingl J.: Drug-induced anaphylactic reactions in children: a retrospective analysis of 159 validated spontaneous reports. Pharmacoepidemiol Drug Saf. 2019, 28(3), 377-388. doi:10.1002/pds.4726

Arulappen AL., Danial M., Sulaiman SAS.: Evaluation of reported adverse drug reactions in antibiotics usage: a retrospective study from a Tertiary Care Hospital, Malaysia. Front Pharmacol. 2018, 9, 809. doi:10.3389/fphar.2018.00809

Yang MS., Kang DY., Seo B., et al.: Incidence of cephalosporins-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: a large multicenter retrospective cohort study. Allergy. 2018, 73(9), 1833–1841. doi:10.1111/all.13435

Del Villar-Guerra P., Vincente-Arche BM., Bustamante SC., Rodríguez CS.: Anaphylactic reaction due to cefuroxime axetil: a rare cause of anaphylaxis. Int J Immunopathol Pharmacol. 2016, 29(4), 731–733. doi:10.1177/0394632016664529

Merget R., Sander I., Fartasch M., et al.: Occupational generalized urticarial and anaphylaxis after inhalation of cefuroxime in a nurse. Am J Ind Med. 2018, 61(3), 261–266. doi:10.1002/ajim.22788

Utku ӦG., Ergül B., Balci M., Oğuz D.: A rare case of ischemic colitis: cefuroxime related anaphylactic shock. Gastroenterol Nurs. 2019, 42(5), 448–450. doi:10.1097/SGA.0000000000000474

Menon AR., Kumar B., Vasavi K., et al.: A case report on linezolid and cefuroxime induced leucocytoclastic vasculitis. J Young Pharm. 2019, 11(2), 227–229. doi:10.5530/jyp.2019.11.47

Kumar D., Niveditha G., Kumar BS., et al.: Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome due to oral cefuroxime. J Clin Sci Res. 2019, 8, 155–158. doi:10.4103/JCSR.JCSR_23_18

Kiran TA., Hiremath SRR., Jaiprakash SV., Pais N.: Study of cefuroxime/oxcarbazepine induced Stevens-Johnson syndrome. Indian J Pharm Pract. 2008, 1, 58–59

Saeed SAM., Bazza M., Zaman M., Ryatt KS.: Cefuroxime induced lymphomatoid hypersensitivity reaction. Postgrad Med J. 2000, 76(899), 577–579. doi:10.1136/pmj.76.899.577

Xiao H., Liu X., Guo X.: Macular edema with serous retinal detachment post‑phacoemulsification followed by spectral domain optical coherence tomography: a report of two cases. BMC Res Notes. 2015, 8, 647. doi:10.1186/s13104-015-1639-1

Grgurević I., Pejša V., Morović-Vergles J., et al.: N. Fatal toxic epidermal necrolysis and severe granulocytopenia following therapy with cefuroxime. Acta Dermatovenerol Croat. 2008, 16(3), 133–137

Sahoo HB., Rath B., Behera JP., Moharana CS.: Cefuroxime axetil associated oral eruption: a case report. Apollo Medicine. 2016, 13(2), 133–134. doi:10.1016/j.apme.2016.05.003

Akman C., Duran A., Kalafat UM., Ocak T.: Uveitis attack and drug reaction due to cefuroxime axetil. Cutan Ocul Toxicol. 2016, 35(3), 254–256. doi:10.3109/15569527.2015.1067817

Pathak A., Pandey AK., Mishra AK., Mishra AK.: Cefuroxime axetil induced glossitis: a case report. Int J Basic Clin Pharmacol. 2014, 3(4), 729–731. doi:10.5455/2319-2003.ijbcp20140809

Vucicevic Boras V., Brailo V., Vidovic Juras D., et al.: Oral adverse reaction to cefuroxime axetil. Annu Res Rev. 2014, 4(15), 2471-2475. doi:10.9734/ARRB/2014/10103

Trucker A., Hegarty P., Magill PJ., et al.: Acute kidney injury after prophylactic cefuroxime and gentamicin in patients undergoing primary hip and knee arthroplasty- a propensity score-matched study. J Arthroplasty. 2018, 33(9), 3009–3015. doi:10.1016/j.arth.2018.04.044

Ekiz F., Üsküdar O., Şimşek Z., et al. Cefuroxime axetil-induced liver failure. Ann Hepatol. 2010, 9(3), 306. doi:10.1016/S1665-2681(19)31645-X

Nirella MA., Kumarasena RS., Dassanayake AS., et al.: Worsening cholestasis and possible cefuroxime-induced liver injury following “successful” therapeutic endoscopic retrograde cholangiopancreatography for a distal common bile duct stone: a case report. J Med. Case Rep. 2016, 10, 371. doi:10.1186/s13256-016-1123-0

Kunze W., Streidl J., Klemm T., Lutze J.: Cefuroxime-induced hepatocellular-cholestatic hepatitis with pancytopenia. OALib J. 2019, 6, 1–7. doi:10.4236/oalib.1105036

Hossain D.: Cefuroxime-induced congenital fixed drug eruption: a case report. J Pakistan Assoc Dermatologists. 2012, 22(4), 379–383

Van Dam DGHA., Burgers DMT., Foudraine N., et al.: Treatment of cefuroxime-induced neurotoxicity with continuous venovenous haemofiltration. Neth J Med. 2017, 75(1), 32–34

Jain M., Aggarwal A.: A probable association of panic attack with cephuroxime (cefuroxime) axetil administration. Prog Neuropsychopharmacol Biol Psychiatry. 2012, 36(1), 211. doi:10.1016/j.pnpbp.2010.11.017 [letter to the editor]

Zahiruddin O., Shanooha M., Mohd Azhar MY.: Psychosis induced by cefuroxime and metronidazole. Med J Malaysia. 2014, 69(1), 33–34

Dong H., Zhang J., Ren L., Zhu S.: Unexpected death due to cefuroxime-induced disulfiram-like reaction. Indian J Pharmacol. 2013, 45(4), 399–400. doi:10.4103/0253-7613.114991

Gao J., Gao Y., Ma J.: Cefuroxime-associated Kounis syndrome with unique peculiarity in perioperative prophylaxis. J Infect Public Health. 2018, 11(6), 889–892. doi:10.1016/j.jiph.2018.02.009

Al-Attas A., Nasr JJ., El-Enany N., Belal F.: A green capillary zone electrophoresis method for the simultaneous determination of piperacillin, tazobactam and cefepime in pharmaceutical formulations and human plasma. Biomed Chromatogr. 2015, 29(12), 1811–1818. doi:10.1002/bmc.3500

Šestáková N., Theurillat R., Sendi P., Thormann W.: Monitoring of cefepime in human serum and plasma by micellar electrokinetic capillary chromatography: improvement of sample preparation and validation by liquid chromatography coupled to mass spectrometry. J Sep Sci. 2017, 40(8), 1805–1814. doi:10.1002/jssc.201601446

Kulapina EG., Kulapina OI., Ankina VD.: Screen-printed potentiometric sensors based on carbon materials for determining cefotaxime and cefuroxime. J Anal Chem. 2020, 75, 231–237. doi:10.1134/S1061934820020100

Alonso JM., Peccinini RG., Campos ML., et al.: Plasma and peritoneal fluid concentration of ceftriaxone after intravenous and intraperitoneal administration in horses. J Equine Vet Sci. 2021, 96, 103310. doi:10.1016/j.jevs.2020.103310

Cox S., Martin A., Hamill M., et al.: Development of a method for the determination of cefovecin in plasma by HPLC. Biomed Chromatogr. 2014, 28(8), 1126–1130. doi:10.1002/bmc.3129

Beaudoin ME., Gangl ET.: Bioanalytical method validation for the simultaneous determination of ceftazidime and avibactam in rat plasma. Bioanalysis. 2016, 8(2), 111–122. doi:10.4155/bio.15.233

Dorn C., Kratzer A., Schießer S., et al.: Determination of total or free cefazolin and metronidazole in human plasma or interstitial fluid by HPLC-UV for pharmacokinetic studies in man. J Chromatogr B Analyt Technol Biomed Life Sci. 2019, 1118-1119, 51–54. doi:10.1016/j.jchromb.2019.04.025

Kratzer A., Schießer S., Matzneller P., et al.: Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV. J Pharm Biomed. 2018, 163, 34–38. doi:10.1016/j.jpba.2018.09.044

Ezquer-Garin C., Ferriols-Lisart R., Alós-Almiñana M., et al.: Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma. Bioanalysis. 2018, 10(7), 461–473. doi:10.4155/bio-2017-0257

Grégoire M., Leroy AG., Bouquié R., et al.: Simultaneous determination of ceftaroline, daptomycin, linezolid and rifampicin concentrations in human plasma by on-line solid phase extraction coupled to high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed. 2016, 118, 17–26. doi:10.1016/j.jpba.2015.10.008

Wang L., Zheng X., Zhong W., et al.: Validation and application of an LC-MS-MS method for the determination of ceftizoxime in human serum and urine. J Chromatogr Sci. 2016, 54(5), 713–719. doi:10.1093/chromsci/bmv243

Sutherland CA., Nicolau DP.: Development of an HPLC method for the determination of ceftolozane/tazobactam in biological and aqueous matrixes. J Chromatogr Sci. 2016, 54(6), 1037–1040. doi:10.1093/chromsci/bmw047

Rigo-Bonin R., Cobo-Sacristán S., Padullés A., et al.: Measurement of ceftazidime concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Application to critically ill patients and patients with osteoarticular infections. Biomed Chromatogr. 2016, 30(3), 410–418. doi:10.1002/bmc.3563

Patil K., Tambe H., Zope V., et al.: Simultaneous determination of zidebactam and cefepime in dog plasma by LC-MS/MS and its application to pre-clinical pharmacokinetic study. Biomed Chromatogr. 2018, 32(8), e4249. doi:10.1002/bmc.4249

Paal M., Zoller M., Schuster C., et al.: Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC-MS/MS method. J Pharm Biomed. 2018, 152, 102–110. doi:10.1016/j.jpba.2018.01.031

Jin HE., Kim IB., Kim YC., et al.: Determination of cefadroxil in rat plasma and urine using LC-MS/MS and its application to pharmacokinetic and urinary excretion studies. J Pharm Biomed. 2014, 947–948, 103-110. doi:10.1016/j.jchromb.2013.12.027

Kano EK., dos Reis Serra CH., Mori Koono EE., et al.: An efficient HPLC-UV method for the quantitative determination of cefadroxil in human plasma and its application in pharmacokinetic studies. J Liq Chromatogr Relat. 2012, 35(13), 1871–1881. doi:10.1080/10826076.2011.627607

Khan A., Iqbal Z., Khn MI., et al. Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: method development, optimization, validation, and its application to a pharmacokinetic study. J Chromatogr B. 2011, 879, 2423–2429. doi:10.1016/j.jchromb.2011.06.040

Information deleted to maintain the anonymity of the review process.

Lecaillon JB., Rouan MC., Souppart C., et al.: Determination of cefsulodin, cefotiam, cephalexin, cefotaxime, desacetyl-cefotaxime, cefuroxime and cefroxadin in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1982, 228, 257–267. doi:10.1016/s0378-4347(00)80438-7

Nowak K., Szpot P., Zawadzki M.: The stability of 4-chloromethcathinone in blood and vitreous humor. J Forensic Sci. 2020, 65(5), 1784–1790. doi:10.1111/1556-4029.14454

Hu X., Huang M., Liu J., et al.: Simple and robust analysis of cefuroxime in human plasma by LC-MS/MS: application to a bioequivalence study. Adv Pharmacol Sci. 2014, 981624. doi:10.1155/2014/981624

Nowak K., Jurek T., Zawadzki M.: Postmortem determination of short-term markers of hyperglycemia for the purposes of medicolegal opinions. Diagnostics. 2020, 10, 236. doi:10.3390/diagnostics10040236

Jantos R., Schuhmacher M., Veldsra JL., et al.: Determination of blood/serum ratios of different forensically relevant analytes in authenticsamples. Arch Kriminol. 2011, 277(5-6), 188–203

Viberg A., Sandström M., Jansson B. Determination of cefuroxime in human serum or plasma by liquid chromatography with electrospraytandem mass spectrometry. Rapid Commun Mass Spectrom. 2014, 18, 707–710. doi:10.1002/rcm.1396

Partini P., Gurule S., Khuroo A., et al.: Liquid chromatography/electrospray tandem mass spectrometry method for the determination of cefuroxime in human plasma: application to a pharmacokinetic study. J Chromatogr B. 2010, 878, 428–434. doi:10.1016/j.jchromb.2009.12.025

Informacje

Informacje: Archiwum Medycyny Sądowej i Kryminologii, 2024, Vol. 74 (3), s. 265 - 279

Typ artykułu: Oryginalny artykuł naukowy

Tytuły:

Angielski:
Determination of cefuroxime in human blood and urine using UHPLC-MS/MS and its application to stability study of cefuroxime over 278 days
Polski:
Oznaczanie cefuroksymu w ludzkiej krwi i moczu metodą UHPLC-MS/MS i jej zastosowanie do badania stabilności cefuroksymu w ciągu 278 dni

Autorzy

Uniwersytet Opolski

https://orcid.org/0000-0003-2146-9724

Marcin Zawadzki
Department of Forensic Medicine, Wroclaw Medical University, Poland
https://orcid.org/0000-0003-2146-9724 Orcid
Wszystkie publikacje autora →

Department of Forensic Medicine, Wroclaw Medical University, Poland

https://orcid.org/0000-0002-5352-3492

Paweł Szpot
Department of Forensic Medicine, Wroclaw Medical University, Poland
https://orcid.org/0000-0002-5352-3492 Orcid
Wszystkie publikacje autora →

Department of Forensic Medicine, Wroclaw Medical University, Poland

Publikacja: 16.12.2024

Status artykułu: Otwarte __T_UNLOCK

Licencja: CC-BY-NC-SA  ikona licencji

Udział procentowy autorów:

Karolina Nowak (Autor) - 33.33%
Marcin Zawadzki (Autor) - 33.33%
Paweł Szpot (Autor) - 33.33%

Korekty artykułu:

-

Języki publikacji:

Angielski

Sugerowane cytowania: Nature

Nowak, K, Zawadzki, M, Szpot, P. Oznaczanie cefuroksymu w ludzkiej krwi i moczu metodą UHPLC-MS/MS i jej zastosowanie do badania stabilności cefuroksymu w ciągu 278 dni. Archiwum Medycyny Sądowej i Kryminologii 2024, 265-279 (2024)